TABLE 1.
Baseline Characteristics According to Polygenic Risk Group
| Polygenic Risk | |||||
|---|---|---|---|---|---|
| Overall (N = 288) |
Low (n = 58) |
Intermediate (n = 172) |
High (n = 58) |
P Value | |
| Age, y | 57.5 ± 7.3 | 57.9 ± 7.6 | 57.3 ± 7.4 | 57.5 ± 6.9 | 0.893 |
| Male | 174 (60) | 30 (52) | 106 (62) | 38 (66) | 0.277 |
| Reason for referral | 0.244 | ||||
| Nonspecific chest pain | 88 (31) | 16 (28) | 58 (34) | 14 (25) | |
| Atypical angina | 105 (37) | 27 (47) | 54 (32) | 24 (42) | |
| Typical angina | 91 (32) | 15 (26) | 57 (34) | 19 (33) | |
| Type 2 diabetes mellitus | 47 (16) | 7 (12) | 27 (16) | 13 (22) | 0.302 |
| Body mass index, kg/m2 | 27.2 ± 4.3 | 26.7 ± 4.4 | 27.0 ± 4.3 | 27.9 ± 3.9 | 0.118 |
| History of smoking | 82 (28) | 21 (36) | 45 (26) | 16 (28) | 0.459 |
| Family history of CAD | 160 (56) | 28 (48) | 103 (60) | 29 (50) | 0.194 |
| Hypertension | 122 (42) | 20 (34) | 72 (42) | 30 (52) | 0.167 |
| Hypercholesterolemia | 109 (38) | 18 (31) | 62 (36) | 29 (50) | 0.081 |
| Statin use | 0.012 | ||||
| No statin | 106 (37) | 27 (47) | 67 (39) | 12 (21) | |
| Low intensity | 3 (1.0) | 1 (1.7) | 2 (1.2) | 0 (0) | |
| Moderate intensity | 146 (51) | 23 (40) | 89 (52) | 34 (59) | |
| High intensity | 33 (11) | 7 (12) | 14 (8.1) | 12 (21) | |
| Beta-blocker use | 175 (62) | 33 (58) | 107 (63) | 35 (61) | 0.794 |
| Aspirin use | 207 (73) | 38 (67) | 121 (71) | 48 (84) | 0.079 |
| Calcium-channel blocker use | 77 (27) | 13 (23) | 47 (28) | 17 (30) | 0.680 |
| LDL cholesterol, mg/dL | 101 ± 38 | 113 ± 40 | 97 ± 35 | 105 ± 40 | 0.056 |
| LDL cholesterol, mg/dL, adjusted for statin usea | 126.87 ± 48.00 | 136 ± 50 | 120 ± 44 | 139 ± 53 | 0.023 |
| HDL cholesterol, mg/dL | 56 ± 20 | 59 ± 19 | 55 ± 18 | 54 ± 23 | 0.301 |
| Triglycerides, mg/dL | 124 (89–188) | 124 (89–151) | 128 (89–195) | 120 (88–210) | 0.476 |
| Total cholesterol, mg/dL | 175 (62) | 33 (58) | 107 (63) | 35 (61) | 0.326 |
| PRS percentile | 50 (25–75) | 10 (5–15) | 50 (35–65) | 90 (85–95) | |
Values are mean ±SD, n (%), or median (Q1-Q3).
a
Low-density lipoprotein (LDL) cholesterol was adjusted for statin use considering an average reduction of 30%.
CAD = coronary artery disease; HDL = high-density lipoprotein; PRS = polygenic risk score.